BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 27532024)

  • 1. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.
    Montalbán Del Barrio I; Penski C; Schlahsa L; Stein RG; Diessner J; Wöckel A; Dietl J; Lutz MB; Mittelbronn M; Wischhusen J; Häusler SFM
    J Immunother Cancer; 2016; 4():49. PubMed ID: 27532024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.
    Häusler SF; Del Barrio IM; Diessner J; Stein RG; Strohschein J; Hönig A; Dietl J; Wischhusen J
    Am J Transl Res; 2014; 6(2):129-39. PubMed ID: 24489992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.
    Marius W; Leticia OF; Friedrich KN; Stephan M; Louisa H; Tabea S; Elisa S; Pauline W; Yi D; Qi M; Barbara S; Carsten B; Walter F; Jasmin W; Franziska B
    Oncoimmunology; 2024; 13(1):2346359. PubMed ID: 38737794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
    Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
    Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer.
    Li J; Wang L; Chen X; Li L; Li Y; Ping Y; Huang L; Yue D; Zhang Z; Wang F; Li F; Yang L; Huang J; Yang S; Li H; Zhao X; Dong W; Yan Y; Zhao S; Huang B; Zhang B; Zhang Y
    Oncoimmunology; 2017; 6(6):e1320011. PubMed ID: 28680754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.
    Shevchenko I; Mathes A; Groth C; Karakhanova S; Müller V; Utikal J; Werner J; Bazhin AV; Umansky V
    Oncoimmunology; 2020 Apr; 9(1):1744946. PubMed ID: 33457090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosinergic Immunosuppression by Human Mesenchymal Stromal Cells Requires Co-Operation with T cells.
    Kerkelä E; Laitinen A; Räbinä J; Valkonen S; Takatalo M; Larjo A; Veijola J; Lampinen M; Siljander P; Lehenkari P; Alfthan K; Laitinen S
    Stem Cells; 2016 Mar; 34(3):781-90. PubMed ID: 26731338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.
    Jacoberger-Foissac C; Cousineau I; Bareche Y; Allard D; Chrobak P; Allard B; Pommey S; Messaoudi N; McNicoll Y; Soucy G; Koseoglu S; Masia R; Lake AC; Seo H; Eeles CB; Rohatgi N; Robson SC; Turcotte S; Haibe-Kains B; Stagg J
    Cancer Immunol Res; 2023 Jan; 11(1):56-71. PubMed ID: 36409930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
    Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
    Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma.
    Cui H; Lan Z; Zou KL; Zhao YY; Yu GT
    Cancer Immunol Immunother; 2023 May; 72(5):1315-1326. PubMed ID: 36436019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer.
    Li L; Wang L; Li J; Fan Z; Yang L; Zhang Z; Zhang C; Yue D; Qin G; Zhang T; Li F; Chen X; Ping Y; Wang D; Gao Q; He Q; Huang L; Li H; Huang J; Zhao X; Xue W; Sun Z; Lu J; Yu JJ; Zhao J; Zhang B; Zhang Y
    Cancer Res; 2018 Apr; 78(7):1779-1791. PubMed ID: 29374065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
    Figueiró F; de Oliveira CP; Bergamin LS; Rockenbach L; Mendes FB; Jandrey EH; Moritz CE; Pettenuzzo LF; Sévigny J; Guterres SS; Pohlmann AR; Battastini AM
    Purinergic Signal; 2016 Jun; 12(2):303-12. PubMed ID: 26910734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.
    d'Almeida SM; Kauffenstein G; Roy C; Basset L; Papargyris L; Henrion D; Catros V; Ifrah N; Descamps P; Croue A; Jeannin P; Grégoire M; Delneste Y; Tabiasco J
    Oncoimmunology; 2016 Jul; 5(7):e1178025. PubMed ID: 27622030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte Macrophage Colony-Stimulating Factor-Activated CD39
    Weinhage T; Däbritz J; Brockhausen A; Wirth T; Brückner M; Belz M; Foell D; Varga G
    Cell Mol Gastroenterol Hepatol; 2015 Jul; 1(4):433-449.e1. PubMed ID: 28210690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation.
    Festag J; Thelemann T; Schell M; Raith S; Michel S; Jaschinski F; Klar R
    Mol Ther Nucleic Acids; 2020 Sep; 21():656-669. PubMed ID: 32739778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Preventive Effect of the Phenotype of Tumour-Associated Macrophages, Regulated by CD39, on Colon Cancer in Mice.
    Park HJ; Seo EH; Piao L; Park ST; Lee MK; Koh SE; Lee SH; Kim SH
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-γ.
    Jeannin P; Duluc D; Delneste Y
    Immunotherapy; 2011 Apr; 3(4 Suppl):23-6. PubMed ID: 21524164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.